Pharma News – MSN Group receives US FDA APPROVAL for BUMETANIDE Injection, ANDA
MSN Group is pleased to announce that we received USFDA APPROVAL for BUMETANIDE Injection, ANDA
1 mg/4 mL (0.25 mg/mL) Single-Dose Vials & 2.5 mg/10 mL (0.25 mg/mL) Multiple-Dose Vials.
REGULATORY APPROVALS UPDATE
MSN Group receives US FDA APPROVAL for BUMETANIDE Injection, ANDA
1 mg/4 ml (0.25 mg/mL) Single-Dose Vials & 2.5 mg/10 ml (0.25 mg/ml) Multiple-Dose Vials.
The product will be made available in the country through our US marketing subsidiary Novadaz Pharmaceuticals.
